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In 1999, the Early Lung Cancer Action Project (ELCAP)published the results of its evaluation of early detection of
lung cancer in high-risk subjects in New York, showing that
low-dose computed tomography (CT) is a sensitive tool for
the identification of non-calcified pulmonary nodules and
early lung cancer.1 A methodological debate then ensued over
the need to demonstrate by means of a randomized controlled
trial (RCT) the reduction of lung cancer mortality for people
included in CT scan screening versus those unscreened or
screened by chest radiograph. In their recent article, the Inter-
national ELCAP group (I-ELCAP) has confirmed (with a
greater number of cases) that CT scan is a sensitive screening
test for early lung cancer and has shown high survival rates
among patients with stage I screen-detected disease.2 Several
other one-arm studies evaluating the screening test at preva-
lence and incidence screening have confirmed its good per-
formance.3,4
CHEST RADIOGRAPH SCREENING
RANDOMIZED TRIALS
Lung cancer screening by chest radiograph, with or
without cytology testing, was introduced more than 30 years
ago, and several RCTs reported the absence of mortality
reduction at the end of follow-up. The conclusion of the most
important international agencies is that chest radiograph is
not suitable as a lung cancer screening test.5 The most
important RCT was the Mayo Lung Screening Project, and
after 16 years of follow-up, an update reinforced its conclu-
sions that mortality had not diminished.6 More recently, the
study has also been updated for incidence rates, and earlier
findings have again been confirmed.7 In particular, an excess
of lung cancer cases detected in the intervention group
suggests over-diagnosis. In the accompanying editorial to the
Mayo Project’s updated mortality results, Black8 discussed in
depth the issue of over-diagnosis bias in chest radiograph
trials as the greater harm associated with lung cancer screen-
ing but was open to the possibility that CT scan screening
could reduce mortality and be highly effective.
In several articles, Miettinen et al. harshly rebutted the
conclusion about over-diagnosis and accused exponents of
pseudoevidence and specious reasoning.9
THE METHODOLOGICAL DEBATE
After the critique by the ELCAP group of so-called
“orthodoxy,”10 a scientific discussion arose about the need for
experimental evaluation. In RCTs, the endpoint is cause-
specific mortality and the comparison between the mortality
rates of the intervention and control arms. The assumption
was that screening would not change the timing of death if
early diagnosis and treatment did not change the natural
history of the disease.
However, in a new perspective based on the experience
of lung cancer screening trials, the RCT is no longer a black
box design. Today, it is designed with detailed data for all the
performance parameters, case characteristics, and (in the new
generation trials) related studies of biomolecular markers,
and possibly quality-of-life and costs.
Analysis of the large dataset of 31,567 screened sub-
jects in the recent I-ELCAP publication showed very high
survival rates for subjects with screen-detected tumors, low
rates of interval cancers, and very poor diagnosis of unre-
sected stage I lung cancer cases.2
There are several factors to be considered in the eval-
uation of survival rates as indicators of screening efficacy.
The first of these factors is lead time. It explains survival
benefit as a consequence of diagnostic anticipation in asymp-
tomatic subjects. In the I-ELCAP study, survival for all tumor
types and sizes detected at screening and in the interval
between screenings was 80%; extremely high when com-
pared with that observed in population-based series (10–15%
at 5 years). Of the 484 patients with lung cancer, 412 were
clinical stage I, and their estimated survival rate was compa-
rable with that observed in stage I cancers at 8 years in the
SEER cancer registries. However, although estimated over 10
years, the rates were based on few cases with long follow-up:
the follow-up range was 1 to 123 months, and the median was
40 months.
Unit of Clinical and Descriptive Epidemiology, CSPO Scientific Institute for
Oncological Prevention, Florence, Italy.
Disclosure: The author declares no conflict of interest.
Address for correspondence: Eugenio Paci, Unit of Clinical and Descriptive
Epidemiology, CSPO, Via San Salvi, 12 50135 Florence, Italy. E-mail:
e.paci@cspo.it
Copyright © 2007 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/07/0205-0045
Journal of Thoracic Oncology • Vol. 2, No. 5, Supplement 1, May 2007 S45
The second factor is the possibility of over-diagnosis,
the detection at screening of cancer cases with long mean
sojourn time. An excess of cases, with low probability of
progression, would inflate survival rates for years. There is no
generally accepted way to distinguish individual cancers with
low and high probabilities of progression. There are two
components of over-diagnosis in screening: the detection of
slowly growing cancers and the detection of cancers in
subjects who would have had low probability of dying of lung
cancer in their lifetime because of competing causes of death.
The third major factor to be discussed is prognostic selection.
There is a greater probability of detecting good prognosis
cancer in studies in which healthy volunteers are selected for
screening, such as the I-ELCAP study, because fast-growing
and more aggressive cancers are less likely to be represented.
THE CT SCAN RANDOMIZED SCREENING TRIALS
The Lung Screening Study was a randomized feasibil-
ity study designed as a pilot for a large RCT.11 A total of 1660
subjects were randomized to CT scan prevalence screening
and one repeat screening and 1658 subjects to chest radio-
graph. With a compliance rate of 96% at baseline and 86% at
1 year, 40 lung cancer cases were diagnosed in the interven-
tion arm and 20 in the chest radiograph arm. Of the cases in
the intervention arm, 48% were stage I, compared with 40%
in the chest radiograph arm. This interim result is the only
currently published result of a randomized screening trial.
Larger RCTs are underway in the United States and
Europe. The National Cancer Institute (NCI) is conducting a
large randomized trial enrolling more than 50,000 subjects
(NSLT),12 and the Nelson study13 has enrolled approximately
18,000 subjects in the Netherlands and Belgium and 4000 in
Denmark. The Italung-CT RCT,14 which is ongoing in the
Italian cities of Florence, Pisa, and Pistoia, has enrolled
patients from general practitioners’ lists: 1613 in the inter-
vention and 1593 in the usual care arms. Subjects were men
and women aged 55–69, smokers (all 20-pack years or more)
or former smokers (who stopped smoking within 10 years)
who were randomized to the active (CT scan for 4 years) or
passive (usual care) arm after informed consent. The third
round of screening is in progress.
All these studies have comparable study designs and
aims—a collaborative effort in evaluating mortality reduction
achieved by lung cancer screening. In a meeting held in
Liverpool recently, several research groups of one-arm and
randomized screening trials have agreed to continue their
collaboration sharing data and clinical experience.
CONCLUSION
The aim of randomized screening trials comparing the
experience of a group of subjects offered a screening regimen
with a comparable, non-screened, or differently screened
group is to demonstrate the reduction of mortality that would
be achieved by the early diagnosis of lung cancers. The aim
of one-arm studies is to evaluate screening performance in
terms of cancer detection, interval cancer cases, tumor char-
acteristics, and survival rates. The crucial difference between
these experimental study types, as I argued in a methodolog-
ical article,15 lies not only in their aims but also in the avail-
ability of the control group experience, against whom the active
arm’s probability of screen detection, tumor characteristics, and
lung cancer survival rates should be compared. Assuming that,
in the absence of intervention, lung cancer will progress and kill
the subject did not take into consideration the possibility of
over-diagnosis—the screen detection of indolent, slow growing,
possibly not growing, lung cancers—which was documented in
the old screening trials.
Although there are commonalities in comparing one-arm
and RCTs, there are also differences between studies. The
differences lie in the pattern of risk of screened subjects, in the
technology used, in recall and detection rates, and in positive
predictive values (which may not be related to the type but to the
specificity of each study design). Only by performing early
comparative work among studies and by sharing the results of
quality evaluations of screening performance will public health
agencies, scientists, and advocates be reassured that the future
results of RCTs will be comparable with the most important and
successful one-arm screening trials. And, hopefully, the scien-
tific community will avoid a war over screening such as has been
seen in the field of breast cancer screening evaluation.
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